BGI SENTIS™ Non-invasive Lung Cancer Panel (ctDNA) was CE Marked in December 2021.

BGI is dedicated to utilizing genomics in order to advance precision medicine for cancer. BGI’s next-generation sequencing assays offer a variety of options, including targeted panels that analyze genes directly linked to specific cancers by well-documented scientific research, and also much larger cancer panels designed for cancer analysis and discovery.

BGI’s cancer panels are designed to identify all four classes of actionable genomic alterations, including base substitutions, insertions and deletions, copy number alterations, and selected fusions. Both tissue samples and liquid biopsy samples are supported.

BGI’s lung cancer panel covers 20 genes（or 13 genes while using ctDNA） with direct therapeutic implications for 42 targeted drugs, including those recommended in the latest NCCN guidelines. The panel detects all classes of genomic alterations including SNV, CNV, InDels, and Fusion using routine FFPE samples, tumor tissue, biopsy, DNA, or peripheral blood.

• Fast

• Accurate

• Affordable



Note: this test is considered a screening test, not a diagnostic test. Before making any treatment decisions, all patients should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate. This testing service has not been cleared or approved by the US FDA and is not available in the USA.